Terms: = Testicular cancer AND ABL1, p150, 25, ENSG00000097007, P00519, v-abl, bcr/abl, JTK7, c-ABL, ABL, BCR-ABL AND Clinical Outcome
16 results:
1. [clinical outcome of postchemotherapy retroperitoneal lymph node dissection and predicting retroperitoneal histology in advanced nonseminomatous germ cell tumours of the testis].
Li XD; Guo SJ; Chen SL; Liu ZF; Dong P; Zhang ZL; Jiang LJ; Yao K; Li YH; Han H; Qin ZK; Liu ZW; Zhou FJ
Zhonghua Wai Ke Za Zhi; 2017 Aug; 55(8):603-607. PubMed ID: 28789511
[No Abstract] [Full Text] [Related]
2. Plasma Cytokines Correlated With Disease Characteristics, Progression-Free Survival, and Overall Survival in testicular Germ-Cell Tumor Patients.
Svetlovska D; Miskovska V; Cholujova D; Gronesova P; Cingelova S; Chovanec M; Sycova-Mila Z; Obertova J; Palacka P; Rajec J; Kalavska K; Usakova V; Luha J; Ondrus D; Spanik S; Mardiak J; Mego M
Clin Genitourin Cancer; 2017 Jun; 15(3):411-416.e2. PubMed ID: 28237180
[TBL] [Abstract] [Full Text] [Related]
3. clinical outcome of Patients with Fibrosis/Necrosis at Post-Chemotherapy Retroperitoneal Lymph Node Dissection for Advanced Germ Cell Tumors.
Mano R; Becerra MF; Carver BS; Bosl GJ; Motzer RJ; Bajorin DF; Feldman DR; Sheinfeld J
J Urol; 2017 Feb; 197(2):391-397. PubMed ID: 27720783
[TBL] [Abstract] [Full Text] [Related]
4. Pelvic Lymph Node Dissection in Patients Treated for Testis cancer: The Memorial Sloan Kettering cancer Center Experience.
Alanee SR; Carver BS; Feldman DR; Motzer RJ; Bosl GJ; Sheinfeld J
Urology; 2016 Sep; 95():128-31. PubMed ID: 27235751
[TBL] [Abstract] [Full Text] [Related]
5. [Spermatocytic seminoma. A tumor with many faces].
Mikuz G
Pathologe; 2014 May; 35(3):232-7. PubMed ID: 24682373
[TBL] [Abstract] [Full Text] [Related]
6. 2-¹⁸fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trial.
Bachner M; Loriot Y; Gross-Goupil M; Zucali PA; Horwich A; Germa-Lluch JR; Kollmannsberger C; Stoiber F; Fléchon A; Oechsle K; Gillessen S; Oldenburg J; Cohn-Cedermark G; Daugaard G; Morelli F; Sella A; Harland S; Kerst M; Gampe J; Dittrich C; Fizazi K; De Santis M
Ann Oncol; 2012 Jan; 23(1):59-64. PubMed ID: 21460378
[TBL] [Abstract] [Full Text] [Related]
7. outcome of different post-orchiectomy management for stage I seminoma: Japanese multi-institutional study including 425 patients.
Kamba T; Kamoto T; Okubo K; Teramukai S; Kakehi Y; Matsuda T; Ogawa O
Int J Urol; 2010 Dec; 17(12):980-7. PubMed ID: 20955354
[TBL] [Abstract] [Full Text] [Related]
8. Recurrent seminomas: clinical features and biologic implications.
Som A; Zhu R; Guo CC; Efstathiou E; Xiao L; Pisters LL; Matin A; Tu SM
Urol Oncol; 2012; 30(4):494-501. PubMed ID: 20822932
[TBL] [Abstract] [Full Text] [Related]
9. The total number of retroperitoneal lymph nodes resected impacts clinical outcome after chemotherapy for metastatic testicular cancer.
Carver BS; Cronin AM; Eggener S; Savage CJ; Motzer RJ; Bajorin D; Bosl GJ; Sheinfeld J
Urology; 2010 Jun; 75(6):1431-5. PubMed ID: 20299079
[TBL] [Abstract] [Full Text] [Related]
10. clinical outcome and predictors of survival in late relapse of germ cell tumor.
Sharp DS; Carver BS; Eggener SE; Kondagunta GV; Motzer RJ; Bosl GJ; Sheinfeld J
J Clin Oncol; 2008 Dec; 26(34):5524-9. PubMed ID: 18936477
[TBL] [Abstract] [Full Text] [Related]
11. Repeat retroperitoneal lymph-node dissection after chemotherapy for metastatic testicular germ cell tumour.
Willis SF; Winkler M; Savage P; Seckl MJ; Christmas TJ
BJU Int; 2007 Oct; 100(4):809-12. PubMed ID: 17711512
[TBL] [Abstract] [Full Text] [Related]
12. clinical outcome of retroperitoneal lymph node dissection after induction chemotherapy for metastatic non-seminomatous germ cell tumors.
Muramaki M; Hara I; Miyake H; Yamada Y; Okada H; Kamidono S
Int J Urol; 2004 Sep; 11(9):763-7. PubMed ID: 15379941
[TBL] [Abstract] [Full Text] [Related]
13. Incidence and clinical outcome of patients with teratoma in the retroperitoneum following primary retroperitoneal lymph node dissection for clinical stages I and IIA nonseminomatous germ cell tumors.
Sheinfeld J; Motzer RJ; Rabbani F; McKiernan J; Bajorin D; Bosl GJ
J Urol; 2003 Oct; 170(4 Pt 1):1159-62. PubMed ID: 14501715
[TBL] [Abstract] [Full Text] [Related]
14. Bleomycin associated pulmonary toxicity: is perioperative oxygen restriction necessary?
Donat SM; Levy DA
J Urol; 1998 Oct; 160(4):1347-52. PubMed ID: 9751352
[TBL] [Abstract] [Full Text] [Related]
15. Comparison of histological results from the resection of residual masses at different sites after chemotherapy for metastatic non-seminomatous germ cell tumours.
Hartmann JT; Candelaria M; Kuczyk MA; Schmoll HJ; Bokemeyer C
Eur J Cancer; 1997 May; 33(6):843-7. PubMed ID: 9291803
[TBL] [Abstract] [Full Text] [Related]
16. Cisplatin-based chemotherapy of primary extragonadal germ cell tumors. A single institution experience.
Gerl A; Clemm C; Lamerz R; Wilmanns W
Cancer; 1996 Feb; 77(3):526-32. PubMed ID: 8630961
[TBL] [Abstract] [Full Text] [Related]
